IBIO (iBio, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings
iBio, Inc. Common Stock (IBIO) is a publicly traded Healthcare sector company. As of May 21, 2026, IBIO trades at $1.71 with a market cap of $70.54M and a P/E ratio of -3.01. IBIO moved +14.67% today. Year to date, IBIO is -9.57%; over the trailing twelve months it is +107.11%. Its 52-week range spans $0.56 to $6.89. Analyst consensus is strong buy with an average price target of $5.80. Rallies surfaces IBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns IBIO stock?
Hedge funds tracked by Rallies that own IBIO include Citadel Advisors and Renaissance Technologies. The latest tracked quarter is Dec 31, 2023. Rallies shows current holdings, share counts, position changes, and 13F ownership context for iBio, Inc. Common Stock.
IBIO Key Metrics
Key financial metrics for IBIO
Metric
Value
Price
$1.71
Market Cap
$70.54M
P/E Ratio
-3.01
EPS
$-0.56
Dividend Yield
0.00%
52-Week High
$6.89
52-Week Low
$0.56
Volume
1.19K
Avg Volume
0
Revenue (TTM)
$300.00K
Net Income
$-27.61M
Gross Margin
0.00%
Top Hedge Funds Holding IBIO
Citadel Advisors holds 25.39K shares of IBIO, changed +0.00% as of Dec 31, 2023.
Renaissance Technologies holds 15.88K shares of IBIO, changed +0.00% as of Mar 31, 2024.
Hedge funds tracked by Rallies that own IBIO include Citadel Advisors and Renaissance Technologies. The latest tracked quarter is Dec 31, 2023. Rallies shows current holdings, share counts, position changes, and 13F ownership context for iBio, Inc. Common Stock.
Does Rallies show 13F holders for IBIO?
Yes. Rallies tracks hedge fund and 13F ownership data for IBIO, including fund names, share counts, latest tracked quarter, and position changes when available.
Is IBIO research on Rallies investment advice?
No. Rallies provides research, data, and educational context for IBIO. It does not provide personalized investment advice.
